Control BionicsASX:CBL 3-Year ROIIC % is 22.48 as of Jun. 2025. The stock has 4 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Control Bionics ranks better than 71.71% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Control Bionics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 22.48%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Control Bionics's 3-Year ROIIC % or its related term are showing as below:
ASX:CBL's 3-Year ROIIC % is ranked better than 71.71% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.67
vs ASX:CBL: 22.48
Control Bionics (ASX:CBL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Control Bionics 3-Year ROIIC % Related Terms
Control Bionics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Control Bionics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Control Bionics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Control Bionics's 3-Year ROIIC % falls into.
Control Bionics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -6.999 (Jun. 2025) - -6.607 (Jun. 2022) )
/
( 5.624 (Jun. 2025) - 7.368 (Jun. 2022) )
=
-0.392
/
-1.744
=
22.48%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Control Bionics (ASX:CBL) has a 3-Year ROIIC % of 22.48 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #226 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 28.3%.
Is Control Bionics' 3-Year ROIIC % too high?
Control Bionics' current 3-Year ROIIC % is 22.48. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.67. Control Bionics' value of 22.48 is 1246.1% above this industry median. Based on the distribution chart, Control Bionics ranks #226 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #226 out of 799 companies for 3-Year ROIIC %. This puts Control Bionics in the upper half of its industry. The industry median 3-Year ROIIC % is 1.67. Control Bionics' value of 22.48 is 1246.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current 3-Year ROIIC % of 22.48 is 1246.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current 3-Year ROIIC % is 22.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.08 — trading 150% above its estimated fair value. The current 3-Year ROIIC % is 22.48 and 1246.1% above the Medical Devices & Instruments industry median of 1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current 3-Year ROIIC % is 22.48 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 